[go: up one dir, main page]

WO2002030959A3 - Peptides derived from smac (diablo) and methods of use therefor - Google Patents

Peptides derived from smac (diablo) and methods of use therefor Download PDF

Info

Publication number
WO2002030959A3
WO2002030959A3 PCT/US2001/032121 US0132121W WO0230959A3 WO 2002030959 A3 WO2002030959 A3 WO 2002030959A3 US 0132121 W US0132121 W US 0132121W WO 0230959 A3 WO0230959 A3 WO 0230959A3
Authority
WO
WIPO (PCT)
Prior art keywords
diablo
smac
peptides derived
methods
use therefor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/032121
Other languages
French (fr)
Other versions
WO2002030959A2 (en
Inventor
Stephen W Fesik
Robert P Meadows
Stephen P Betz
Zhihong Liu
Edward T Olejniczak
Chaohong Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of WO2002030959A2 publication Critical patent/WO2002030959A2/en
Publication of WO2002030959A3 publication Critical patent/WO2002030959A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to peptides derived from the wildtype human smac (DIABLO) protein which binds to a member of an IAP family member. The peptides of the present invention can be used in an assay to identify candidate substances which induce or promote apoptosis in cells.
PCT/US2001/032121 2000-10-13 2001-10-12 Peptides derived from smac (diablo) and methods of use therefor Ceased WO2002030959A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68754900A 2000-10-13 2000-10-13
US09/687,549 2000-10-13

Publications (2)

Publication Number Publication Date
WO2002030959A2 WO2002030959A2 (en) 2002-04-18
WO2002030959A3 true WO2002030959A3 (en) 2002-09-26

Family

ID=24760847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/032121 Ceased WO2002030959A2 (en) 2000-10-13 2001-10-12 Peptides derived from smac (diablo) and methods of use therefor

Country Status (1)

Country Link
WO (1) WO2002030959A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835393B2 (en) 2008-08-02 2014-09-16 Genentech, Inc. Inhibitors of IAP
US8907092B2 (en) 2007-04-30 2014-12-09 Genentech, Inc. Inhibitors of IAP
US9040706B2 (en) 2004-12-20 2015-05-26 Genentech, Inc. Pyrrolidine inhibitors of IAP

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026775A2 (en) * 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions and methods for regulating apoptosis
WO2004005248A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
AU2005218555B2 (en) 2004-03-01 2008-01-03 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
JP5122275B2 (en) 2004-03-23 2013-01-16 ジェネンテック， インコーポレイテッド Azabicyclo-octane inhibitors of IAP
NZ588799A (en) 2004-07-02 2012-06-29 Genentech Inc Inhibitors of iap
US7749520B2 (en) 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
WO2006020060A2 (en) 2004-07-15 2006-02-23 Tetralogic Pharmaceuticals Corporation Iap binding compounds
WO2006091972A2 (en) 2005-02-25 2006-08-31 Tetralogic Pharmaceuticals Dimeric iap inhibitors
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
AU2006308453B9 (en) 2005-10-25 2011-12-01 Pharmascience Inc. IAP BIR domain binding compounds
EP1973899A4 (en) 2005-12-19 2010-10-20 Genentech Inc IPA INHIBITORS
TWI543988B (en) 2006-03-16 2016-08-01 科學製藥股份有限公司 Iap bir domain binding compounds
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
WO2008014252A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Iap inhibitors
AR063943A1 (en) 2006-07-24 2009-03-04 Tetralogic Pharmaceuticals Cor IAP ANTAGONIST DIPEPTIDES, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM AND THE USE OF THEM FOR THE TREATMENT OF CANCER.
CA2671607A1 (en) 2006-12-19 2008-07-03 Genentech, Inc. Imidazopyridine inhibitors of iap
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
EP2534170B1 (en) 2010-02-12 2017-04-19 Pharmascience Inc. Iap bir domain binding compounds
CN110713546B (en) * 2019-10-31 2021-04-20 中国医科大学附属第一医院 Antitumor polypeptide Sur-X targeting survivin-XIAP complex and its application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021015A2 (en) * 1997-10-21 1999-04-29 Cranfield University Affinity ligands, their production and use
WO2002016418A2 (en) * 2000-08-24 2002-02-28 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
WO2002016402A2 (en) * 2000-08-23 2002-02-28 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002026775A2 (en) * 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions and methods for regulating apoptosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021015A2 (en) * 1997-10-21 1999-04-29 Cranfield University Affinity ligands, their production and use
WO2002016402A2 (en) * 2000-08-23 2002-02-28 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002016418A2 (en) * 2000-08-24 2002-02-28 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
WO2002026775A2 (en) * 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions and methods for regulating apoptosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAI JIJIE ET AL: "STRUCTURAL AND BIOCHEMICAL BASIS OF APOPTOTIC ACTIVATION BY SMAC/DIABLO.", NATURE (LONDON), vol. 406, no. 6798, 2000, pages 855 - 862, XP002200489, ISSN: 0028-0836 *
DU CHUNYING ET AL: "Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 102, no. 1, 7 July 2000 (2000-07-07), pages 33 - 42, XP002175396, ISSN: 0092-8674 *
VERHAGEN ANNE M ET AL: "IDENTIFICATION OF DIABLO, A MAMMALIAN PROTEIN THAT PROMOTES APOPTOSIS BY BINDING TO AND ANTAGONIZING IAP PROTEINS", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 102, 7 July 2000 (2000-07-07), pages 43 - 53, XP002175397, ISSN: 0092-8674 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9040706B2 (en) 2004-12-20 2015-05-26 Genentech, Inc. Pyrrolidine inhibitors of IAP
US8907092B2 (en) 2007-04-30 2014-12-09 Genentech, Inc. Inhibitors of IAP
US8835393B2 (en) 2008-08-02 2014-09-16 Genentech, Inc. Inhibitors of IAP

Also Published As

Publication number Publication date
WO2002030959A2 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
WO2002030959A3 (en) Peptides derived from smac (diablo) and methods of use therefor
AU2002318112B2 (en) Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
WO2002032925A3 (en) Protein scaffolds for antibody mimics and other binding proteins
WO2003045310A3 (en) Digital assay
AU2001286730A1 (en) An iap binding peptide or polypeptide and methods of using the same
WO2002020568A3 (en) Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins
BR0009206A (en) Protein isolation and analysis
AU2002321931A1 (en) Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
WO2001057198A3 (en) Methods of generating protein expression arrays and the use thereof in rapid screening
EP1136547A3 (en) Adamts polypeptides, nucleic acids encoding them, and uses thereof
AU2002214542A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2001045738A3 (en) Use of heat shock proteins to enhance production of chemokines by a cell
AU2001250999A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
AU2002213450A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
AU2002239256A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
GB0122200D0 (en) Concentration of protein and/or peptide samples
WO2002094777A3 (en) Methods of detecting protein arginine methyltransferase, and uses related thereto
AU2002365084A1 (en) Method and reagent for the detection of proteins and peptides
WO2004094989A3 (en) Methods of host cell protein analysis
EP1134286A3 (en) Adamts polypeptides, nucleic acids encoding them, and uses thereof
WO2003100075A3 (en) Bsnd nucleic acids and proteins
AU2001288363A1 (en) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
AU2001229697A1 (en) Novel molecules of the card-related protein family and uses thereof
WO2000057184A3 (en) Screening methods based on fha domains
WO2003087145A3 (en) Purified polypeptides involved in quorum sensing

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP